Shuitu Feng
Overview
Explore the profile of Shuitu Feng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin G, Wang Z, Chu Q, Hu Y, Huang D, Wang J, et al.
Thorac Cancer
. 2024 Jan;
15(5):419-426.
PMID: 38219795
Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs);...
2.
Huang D, Lin G, Chu Q, Hu Y, Wang J, Wang Z, et al.
Thorac Cancer
. 2023 Nov;
14(34):3421-3429.
PMID: 37963454
Immune checkpoint inhibitors (PD-1/PD-L1 and CTLA-4 blockade) have revolutionized the treatment landscape in non-small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clinical...
3.
Huang K, Lin Y, Qiu G, Wang S, Feng L, Zheng Z, et al.
Aging (Albany NY)
. 2023 Aug;
15(16):8113-8136.
PMID: 37595258
Objective: Pyroptosis is a form of programmed cell death that is essential for immunity. Herein, this study was conducted to uncover the implication of pyroptosis in immunomodulation and tumor microenvironment...
4.
Wang W, Wang Q, Xu C, Li Z, Song Z, Zhang Y, et al.
Thorac Cancer
. 2022 Oct;
13(23):3420-3430.
PMID: 36268845
Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical...
5.
Lin Y, Huang K, Cai Z, Chen Y, Feng L, Gao Y, et al.
Front Pharmacol
. 2022 Jun;
13:884090.
PMID: 35721114
Gastric cancer (GC) is a highly heterogeneous malignant carcinoma. This study aimed to conduct an exosome-based classification for assisting personalized therapy for GC. Based on the expression profiling of prognostic...
6.
Zhang R, Guo T, Ji L, Yin Y, Feng S, Lu W, et al.
Front Oncol
. 2021 Nov;
11:716339.
PMID: 34778032
Human gastrointestinal cancer (e.g., gastric cancer and colorectal cancer) has been a leading cause of cancer-related deaths worldwide and has imposed a great threat to the public health. Although early-stage...
7.
Feng L, Feng S, Nie Z, Deng Y, Xuan Y, Chen X, et al.
Biomed Res Int
. 2021 Aug;
2021:3431245.
PMID: 34409101
TRAF6 has been reported to be associated with poor prognosis in non-small-cell lung cancer (NSCLC). However, its precise role in tumor development has not been elaborated. In the present study,...
8.
Lin R, Lin S, Feng S, Wu Q, Fu J, Wang F, et al.
J Natl Compr Canc Netw
. 2021 Aug;
19(10):1148-1155.
PMID: 34343968
Background: Opioid titration is necessary to achieve rapid, safe pain relief. Medication can be administered via patient-controlled analgesia (PCA) or by a healthcare provider (non-PCA). We evaluated the efficacy of...
9.
Feng S, Qiu G, Yang L, Feng L, Fan X, Ren F, et al.
Biosci Rep
. 2021 Jan;
41(1).
PMID: 33393595
The curative effect for patients with advanced gastric cancer is still unsatisfactory. Proton pump inhibitors could be a promising treatment strategy that could sensitize gastric cancer cells to antitumor drugs...
10.
Feng S, Zheng Z, Feng L, Yang L, Chen Z, Lin Y, et al.
Oncol Rep
. 2016 Oct;
36(6):3207-3214.
PMID: 27748935
The cancer stem cell (CSC) model suggests that a small subset of cancer cells possess stem cell properties and plays a crucial role in tumor initiation, metastasis and resistance to...